Iwaki-Egawa S, Watanabe Y, Fujimoto Y
Department of Clinical Biochemistry, Hokkaido Institute of Pharmaceutical Sciences, Otaru, Japan.
Cell Immunol. 1997 Jun 15;178(2):180-6. doi: 10.1006/cimm.1997.1123.
In this paper, we describe further characterization of the membrane-associated molecule CD26/dipeptidyl peptidase IV (DPP IV), which is said to be adenosine deaminase-binding protein (ADA-bp) in humans, to clarify its association with ADA in rat immune cells. For this purpose, we used three types of rats: DPP IV+ rats; DPP IV- rats, which lack enzyme activity and immunological reactivity of DPP IV; and ADA- rats, which have reduced ADA activity due to continuous peritoneal injection of 2'-DCF, a potent inhibitor of ADA. ADA existed in the cells of DPP IV+ and DPP IV- rats, but it did not exist on the cell surface in either rat. ADA- rats showed a decrease in ADA activity and in the number of immune cells, but no effect on DPP IV was observed. These data suggest that in rats, in contrast to humans, DPP IV does not exist as ADA-bp.
在本文中,我们描述了膜相关分子CD26/二肽基肽酶IV(DPP IV)的进一步特性,该分子在人类中被称为腺苷脱氨酶结合蛋白(ADA-bp),以阐明其在大鼠免疫细胞中与ADA的关联。为此,我们使用了三种类型的大鼠:DPP IV+大鼠;DPP IV-大鼠,其缺乏DPP IV的酶活性和免疫反应性;以及ADA-大鼠,由于连续腹腔注射ADA的强效抑制剂2'-DCF,其ADA活性降低。ADA存在于DPP IV+和DPP IV-大鼠的细胞中,但在两种大鼠的细胞表面均不存在。ADA-大鼠的ADA活性和免疫细胞数量减少,但未观察到对DPP IV有影响。这些数据表明,与人类不同,在大鼠中DPP IV不作为ADA-bp存在。